Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Gut bacteria boost: probiotic shows promise for constipation relief

NCT ID NCT07649564

Symptom relief Sponsor: Wecare Probiotics Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a daily probiotic called Weizmannia coagulans BC99 can improve symptoms of chronic constipation in adults. One hundred participants took either the probiotic or a placebo for a period, and researchers measured changes in stool consistency and gut bacteria. The goal was to see if the probiotic could ease constipation without the need for laxatives.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Weizmannia coagulans BC99 probiotic
What this could lead to
If it works, this could offer a natural, over-the-counter option to help relieve chronic constipation without harsh laxatives.
What could go wrong
This is a small, completed trial with only 100 participants, so results may not apply to everyone. The effect may be modest and not a cure for underlying causes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Jul 2024

Finished

Oct 2024

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: (1) Chinese adults aged 18-70 years who meet the Rome IV diagnostic criteria for chronic constipation (duration of at least 6 months, with less than three passing stools per week and/or Bristol Stool Scale types 1 and 2); (2) The patient rarely experiences diarrhea without using laxatives; (3) The criteria for irritable bowel syndrome were insufffcient ; (4) patients that could complete the study according to the requirements of the trial protocol; (5) participants (including male subjects) who have no family planning within 14 days prior to screening and voluntarily take effective contraceptive measures within 6 months after the end of the trial; (6) Patients capable of understanding the clinical study and willing to comply with the study requirements and procedures; (7) Subjects who have signed the informed consent form. Only those who meet all the above conditions can be selected for the study. \- Exclusion Criteria: 1. Use of probiotics, prebiotics, or antibiotics within two weeks prior to enrollment and throughout the intervention period; 2. Regular use of a high-fiber diet, as measured by the recommended food score (RFS); 3. Regular use of medications affecting bowel habits, such as irritable bowel syndrome, functional bloating, and functional diarrhea; 4. Currently have, or have had in the past 2 years, any gastrointestinal conditions such as: Crohn's disease, celiac disease, ulcerative colitis, malignant tumor of the colon; 5. Medical history of cardiovascular, liver, or renal diseases; alcoholics; 6. Hypersensitivity to probiotics or the ingredients used in this study; 7. Pregnancy or breastfeeding; 8. Participation in another clinical trial in the 3 months before enrollment. -

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic constipation are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

constipation disorder neurodegeneration, childhood-onset, stress-induced, with variable ataxia and seizures neuroendocrine cell hyperplasia of infancy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CON Con S ti Cons ti

Contacts and locations

Locations

  • The School of Food and Bioengineering, Henan University of Science and Technolog

    Luoyang, Henan, 471000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.